Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

YNHH to break ground for neuroscience center

Yale New Haven Hospital plans to break ground on its new $838 million neurosciences center at its Saint Raphael campus, two years after delaying the project...

| By Kelley Gipson

Bioasis brings hope re rare and orphan diseases

With the acquisition of Phase 2 ready assets from Cresence AS, Bioasis becomes a clinical stage company with a multi-asset pipeline focused on rare and orphan drugs....

| By Kelley Gipson

Trevi reports two late-breaking abstracts

Trevi Therapeutics reports that two late-breaking abstracts have been accepted for presentation at upcoming fall medical conferences. The previously disclosed positive interim data from CANAL, a phase...

| By Kelley Gipson

Yale team and NIH tackle glioblastoma

A type of tumor called glioblastoma is the most common brain cancer in adults. It’s also one of the most lethal tumor types overall. Only...

| By Kelley Gipson

Weekly Roundup – August 25, 2022 

View this email in your browser Weekly Roundup – August 25, 2022  Congratulations to ABCT on their recent nomination for the Prix Galien USA Award for Incubators, Accelerators,...

| By Kelley Gipson

Connecticut biotech companies now hiring!

Looking for a job in the biotech industry? Connecticut companies are hiring! Here’s a brief sampling of some open positions. You’ll find them and much...

| By Kelley Gipson

Precipio launches same-day cancer diagnostics

New Haven-based Precipio, a cancer diagnostics company, has launched new one-step technology that enables same-day test results. Keith Meadors, senior vice president of Precipio’s products division,...

| By Kelley Gipson

Career News – August 23, 2022 

View this email in your browser Career News – August 23, 2022  To register for the University of New Haven’s Fall 2022 Career Expo, go...

| By Kelley Gipson

Bristol Myers Squibb expands oncology portfolio

Bristol Myers Squibb has completed its acquisition of Turning Point Therapeutics. “Turning Point has distinguished itself in the field of precision oncology, and this acquisition will...